Arcus Biosciences shares rose on October 20, 2026, following new kidney cancer data from its ARC-20 study. The company reported median overall survival of 35 months in heavily pretreated patients receiving casdatifan alone, while combination-treatment results supported its plans for further late-stage trials.
Key Takeaways
- The 35-month median survival result came from 121 patients across four pooled casdatifan monotherapy cohorts.
- ARC-20 also produced first- and second-line combination data, using a September 4, 2026 cutoff.
- Casdatifan remains investigational, and comparisons with other studies do not establish head-to-head superiority.
Table of Contents
- Arcus Biosciences reports late-line survival results
- Combination results extend the development case
- Phase 3 plans remain the next development milestone
- Conclusion
Arcus Biosciences reports late-line survival results
The company’s October 2026 ARC-20 announcement detailed results for casdatifan, an investigational inhibitor of hypoxia-inducible factor 2-alpha, or HIF-2α. The platform study is testing the drug alone and with other treatments for clear cell renal cell carcinoma, a form of kidney cancer.
The late-line survival finding came from four pooled monotherapy cohorts with 28 months of median follow-up. Patients had previously received both an anti-PD-1 therapy and a VEGFR tyrosine kinase inhibitor; 52% had received at least three prior lines of treatment.
The pooled result provides evidence for continued development in heavily treated patients, but it is not an approval decision or a direct comparison with an existing therapy. Arcus said no unexpected safety signals were observed and described adverse events across the tested doses as acceptable and manageable.
| Item | Details |
|---|---|
| Data cutoff | September 4, 2026, for all reported ARC-20 cohorts. |
| Late-line monotherapy | Median progression-free survival of 13 months; confirmed objective response rate of 36%. |
| First-line casdatifan plus zimberelimab | Six-month progression-free survival of 86%; confirmed objective response rate of 50%. |
| Second-line casdatifan plus cabozantinib | 18-month overall survival of 77%; confirmed objective response rate of 44%. |
Combination results extend the development case
In the first-line cohort, casdatifan plus zimberelimab produced a 12-month progression-free survival rate of 69% among 30 patients, with 11.5 months of median follow-up. Progression-free survival measures the time patients remain alive without their cancer worsening.
For second-line treatment, casdatifan plus cabozantinib achieved median progression-free survival of 14.5 months among 43 patients, with 21.3 months of median follow-up. Arcus said efficacy was similar whether or not patients had previously received a tyrosine kinase inhibitor.
These are separate treatment cohorts with different patient populations and follow-up periods. Their results should not be read as a ranking of the regimens.
Phase 3 plans remain the next development milestone
Arcus is already evaluating casdatifan plus cabozantinib in the Phase 3 PEAK-1 study. It said PEAK-20, a first-line Phase 3 trial of casdatifan plus ipilimumab and nivolumab, remained on track to start in the fourth quarter of 2026.
The company also plans a registrational trial comparing casdatifan plus tivozanib with tivozanib alone. That is a planned study, not a completed test of the combination.
Arcus cautioned that its comparisons with third-party treatment benchmarks were not head-to-head trials. Differences in populations, trial designs and eligibility criteria limit those comparisons. Casdatifan has not received regulatory approval, and its safety and efficacy have not been established.
Conclusion
The ARC-20 results broaden the clinical evidence behind casdatifan, without resolving its regulatory prospects. The next scheduled development milestone is the planned fourth-quarter 2026 start of PEAK-20, alongside the ongoing PEAK-1 trial.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
